About us
The focus of Savine Therapeutics Pty Ltd (“Savine” or the “Company”) is to co-develop and partner with existing vaccine programs that are targeting serious diseases where there is a substantial un-met clinical need. Savine is the owner of the proprietary Scrambled Antigen Vaccine (SAVINE) technology which offers licensees three specific competitive advantages (see page entitled “Competitive Advantages”).
The technology was invented by researchers in the Vaccine Immunology Group at the John Curtin School of Medical Research (JCSMR), Canberra, Australia and is suitable for cancers and infectious diseases. The applications where data exists to support the deployment of this proprietary technology include:
- Nasopharyngeal carcinoma (NPC) and lymphoma
- Tuberculosis (TB)
- HIV
- Hepatitis C (HCV)
Other targeted applications include, but are not limited to:
- Breast cancer
- Colon cancer
- Melanoma
- Rotaviruses
- Influenza